ATE550037T1 - Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen - Google Patents

Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen

Info

Publication number
ATE550037T1
ATE550037T1 AT05817101T AT05817101T ATE550037T1 AT E550037 T1 ATE550037 T1 AT E550037T1 AT 05817101 T AT05817101 T AT 05817101T AT 05817101 T AT05817101 T AT 05817101T AT E550037 T1 ATE550037 T1 AT E550037T1
Authority
AT
Austria
Prior art keywords
sars coronavirus
compositions against
sars
coronavirus
compositions
Prior art date
Application number
AT05817101T
Other languages
English (en)
Inventor
Meulen Jan Ter
Den Brink Edward Norbert Van
Kruif Cornelis Adriaan De
Jaap Goudsmit
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE550037T1 publication Critical patent/ATE550037T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05817101T 2004-11-11 2005-11-10 Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen ATE550037T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62777304P 2004-11-11 2004-11-11
EP04105684 2004-11-11
EP04106192 2004-11-30
EP05102117 2005-03-17
EP05107288 2005-08-08
PCT/EP2005/055876 WO2006051091A1 (en) 2004-11-11 2005-11-10 Compositions against sars-coronavirus and uses thereof

Publications (1)

Publication Number Publication Date
ATE550037T1 true ATE550037T1 (de) 2012-04-15

Family

ID=35747767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05817101T ATE550037T1 (de) 2004-11-11 2005-11-10 Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen

Country Status (9)

Country Link
US (1) US8106170B2 (de)
EP (1) EP1812067B1 (de)
KR (1) KR101255861B1 (de)
AT (1) ATE550037T1 (de)
AU (1) AU2005303758B2 (de)
CA (1) CA2582057C (de)
NZ (1) NZ553701A (de)
SG (1) SG159542A1 (de)
WO (1) WO2006051091A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP1573012B1 (de) 2002-12-17 2011-11-30 Crucell Holland B.V. Rekombinanter virus-basierter malaria impfstoff
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
JP4852046B2 (ja) * 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
BRPI0518146A (pt) * 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2007044695A2 (en) * 2005-10-07 2007-04-19 Dana-Farber Cancer Institute ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
US7728110B2 (en) 2006-05-19 2010-06-01 Amgen, Inc. Antibodies to SARS coronavirus
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009128963A2 (en) * 2008-01-17 2009-10-22 Humab, Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
CN102076263B (zh) 2008-06-30 2013-06-19 皇家飞利浦电子股份有限公司 频谱ct
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (de) * 2010-04-07 2016-09-28 Agency For Science, Technology And Research Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2021148884A1 (en) * 2020-01-24 2021-07-29 Tychan Pte. Ltd. Anti-wuhan coronavirus antibodies
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
JP2023517234A (ja) 2020-03-09 2023-04-24 アブセレラ バイオロジクス インコーポレイテッド 抗コロナウイルス抗体および使用の方法
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021205408A1 (en) * 2020-04-10 2021-10-14 Igy Immune Technologies And Life Sciences Inc. Igy immunoglobulins targeting coronavirus, methods of preparing same, and methods of using same
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
WO2021232041A1 (en) * 2020-05-09 2021-11-18 Baylor College Of Medicine N-acetylcysteine and glycine for treatment of covid-19 and post covid-19 symptoms
KR20230009466A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 SARS-CoV-2 백신
GB202007312D0 (en) * 2020-05-18 2020-07-01 Synthetic Vac Ltd Mimotope peptides of the spike protein from the sars-cov-2 virus
EP4165077A1 (de) * 2020-06-12 2023-04-19 VIR Biotechnology, Inc. Antikörpertherapien für sars-cov-2-infektion
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CN116635410A (zh) * 2020-07-06 2023-08-22 旗舰开拓创新六世公司 靶向SARS-CoV-2的抗原结合分子
CA3183367A1 (en) * 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
US20230058162A1 (en) * 2020-07-27 2023-02-23 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022029011A1 (en) * 2020-08-06 2022-02-10 BioNTech SE Binding agents for coronavirus s protein
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
EP3970798A1 (de) * 2020-09-18 2022-03-23 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Sars-cov-2-nanokörper
WO2022067020A1 (en) * 2020-09-24 2022-03-31 The Broad Institute, Inc. Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
AU2021376384B2 (en) * 2020-11-06 2026-04-16 Cho Pharma, Inc. Immune composition comprising antigen and glycoengineered antibody thereof
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
EP4370681A4 (de) * 2021-07-16 2025-11-19 Biocad Joint Stock Co Auf influenzavirus basierendes isoliertes rekombinantes virus
EP4722239A3 (de) 2021-08-20 2026-07-15 Christopher E. Rudd Zusammensetzungen und verfahren für chimären antivirus-antigenrezeptor
CN113908264B (zh) * 2021-10-21 2023-06-23 中国人民解放军空军军医大学 基于噬菌体载体的新型冠状病毒疫苗及其制备方法
IL316848A (en) 2022-05-06 2025-01-01 Generate Biomedicines Inc Antigen-binding molecules targeting SARS-CoV-2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0934526B1 (de) 1996-10-08 2003-01-08 U-BISys B.V. Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US7329530B2 (en) 2001-06-15 2008-02-12 Crucell Holland B.V. Chimaeric phages
FR2828405B1 (fr) 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
WO2004111081A2 (en) 2003-06-13 2004-12-23 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
EP1646645A1 (de) 2003-07-21 2006-04-19 Crucell Holland B.V. Antigene peptide des sars-coronavirus und anwendungen davon
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
WO2005047459A2 (en) 2003-08-04 2005-05-26 University Of Massachusetts Sars nucleic acids, proteins, antibodies, and uses thereof
CN1914226B (zh) * 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法

Also Published As

Publication number Publication date
AU2005303758B2 (en) 2011-04-28
WO2006051091A1 (en) 2006-05-18
NZ553701A (en) 2009-12-24
CA2582057C (en) 2015-08-11
SG159542A1 (en) 2010-03-30
AU2005303758A1 (en) 2006-05-18
US20080014204A1 (en) 2008-01-17
KR20070083768A (ko) 2007-08-24
CA2582057A1 (en) 2006-05-18
KR101255861B1 (ko) 2013-04-17
EP1812067B1 (de) 2012-03-21
US8106170B2 (en) 2012-01-31
EP1812067A1 (de) 2007-08-01

Similar Documents

Publication Publication Date Title
SG159542A1 (en) Compositions against sars-coronavirus and uses thereof
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ECSP088107A (es) Inhibidores de la proteasa ns3 del vhc
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008051477A3 (en) Hcv ns3 protease inhibitors
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
EA201100084A1 (ru) Сшиваемая полимерная композиция
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
DE602007009865D1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
EA200801739A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
BRPI0612124A2 (pt) derivados de heteroarila para o tratamento de viroses
EA201000069A1 (ru) Новые гербициды
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer